Evidence map›Paper›PMID 41859441›Full record

ArticleFrontiers in microbiology2026

Optimally fixed F protein on the surface of RSV-infected cells for RSV binding and neutralizing assays.

Hongsheng Qiang, Yujin Shi, Zemin Jiang, Yuhao Fu, Xiaobin Zhang, Li Chen, Yongpeng Sun, Yangling Wu, Zizheng Zheng, Ningshao Xia

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hongsheng Qiang *State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, Fujian, China.
Yujin Shi *State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, Fujian, China.
Zemin Jiang *State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, Fujian, China.
Yuhao FuState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, Fujian, China.
Xiaobin ZhangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, Fujian, China.
Li ChenState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, Fujian, China.
Yongpeng SunState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, Fujian, China.
Yangling WuEmergency Department, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China.
Zizheng ZhengState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, Fujian, China.
Ningshao XiaState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, Fujian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Respiratory syncytial virus (RSV) presents a significant global public health challenge, contributing substantially to the disease burden worldwide. As numerous F protein-based vaccine candidates advance into clinical trials, robust evaluation methods are essential. Here, we developed a cell-based ELISA platform to rapidly evaluate serum antibody responses to these vaccines. By treating RSV-infected cells with 4% formaldehyde or 60% methanol, the cell-surface F proteins were stabilized in the pre-fusion (pre-F) or post-fusion (post-F) conformations, respectively. This platform efficiently determines the binding and neutralizing activities of post-immunization serum antibodies, providing an effective method for evaluating the efficacy of RSV vaccine candidates.

Indexed as

binding antibody titercell-based ELISAF proteinneutralizing antibody titerRSV

Identifiers

PMID41859441
PMCPMC12996122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.